Abstract

POS0228 MINIMAL IMPORTANT DIFFERENCE (MID), MINIMAL DETECTABLE CHANGE (MDC), AND DISEASE ACTIVITY THRESHOLDS FOR TWO NOVEL COMPOSITE INSTRUMENTS (3VAS, 4VAS) IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THREE PHASE...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis.
Justine Y Ye ... Anthony V Perruccio
Rheumatology (Oxford, England) | VOL. 59
Justine Y Ye, et. al.Justine Y Ye ... Anthony V Perruccio
14 Jun 2019
SAT0295 Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data from an Interventional Study with Golimumab.
P Helliwell ... A Kavanaugh
Annals of the Rheumatic Diseases | VOL. 72
P Helliwell, et. al.P Helliwell ... A Kavanaugh
01 Jun 2013
OP0224 CONTINUOUS COMPOSITE MEASURES FOR ROUTINE CARE IN PSORIATIC ARTHRITIS: THRESHOLDS OF MEANING AND CLINICALLY IMPORTANT DIFFERENCE ESTIMATES FOR THE 3 AND 4 VAS SCALES FROM A UK MULTICENTRE STUDY
P Helliwell ... L C Coates
Annals of the Rheumatic Diseases | VOL. 80
P Helliwell, et. al.P Helliwell ... L C Coates
19 May 2021
AB0753 COMPARING COMPOSITE MEASURES OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL WITH GUSELKUMAB
Dafna D Gladman ...
-
Dafna D Gladman, et. al.Dafna D Gladman ...
01 Jun 2019
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers